How to buy Akari Therapeutics stock (AKTX)

Akari Therapeutics is a biotechnology business based in the US. Akari Therapeutics shares (AKTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.98 – a decrease of 1.99% over the previous week. Akari Therapeutics employs 6 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Akari Therapeutics stock

Buy Akari Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Akari Therapeutics stock price (NASDAQ: AKTX)

Use our graph to track the performance of AKTX stocks over time.

Akari Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-22.

Latest market close	$0.98
52-week range	$0.90 - $4.40
50-day moving average more info button	$2.67
200-day moving average more info button	$2.55
Wall St. target price	$80.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.58

Is it a good time to buy Akari Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Akari Therapeutics price performance over time

Historical closes compared with the close of $0.98 from 2024-12-24

1 week (2024-12-19)	-1.99%
1 month (2024-11-27)	-12.50%
3 months (2024-09-26)	-67.87%
6 months (2024-06-26)	-63.97%

1 year (2023-12-26)	-67.44%
2 years (2022-12-23)	-89.11%
3 years (2021-12-23)	30.8
5 years (2019-12-26)	34.7

Akari Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-172.83%
Return on equity TTM	-1281.43%
Profit margin	0%
Book value	$-0.04
Market Capitalization more info button	$30.3 million

TTM: trailing 12 months

Akari Therapeutics share dividends

We're not expecting Akari Therapeutics to pay a dividend over the next 12 months.

Have Akari Therapeutics's shares ever split?

Akari Therapeutics's shares were split on a 1:20 basis on 16 August 2023 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Akari Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Akari Therapeutics shares which in turn could have impacted Akari Therapeutics's share price.

Akari Therapeutics share price volatility

Over the last 12 months, Akari Therapeutics's shares have ranged in value from as little as $0.9 up to $4.4. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akari Therapeutics's is 0.951. This would suggest that Akari Therapeutics's shares are less volatile than average (for this exchange).

Akari Therapeutics overview

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts. .

Frequently asked questions

null
What percentage of Akari Therapeutics is owned by insiders or institutions?
Currently 11.91% of Akari Therapeutics shares are held by insiders and 0.508% by institutions. How many people work for Akari Therapeutics?
Latest data suggests 6 work at Akari Therapeutics. When does the fiscal year end for Akari Therapeutics?
Akari Therapeutics's fiscal year ends in December. Where is Akari Therapeutics based?
Akari Therapeutics's address is: 22 Boston Wharf Road, Boston, MA, United States, 02210 What is Akari Therapeutics's ISIN number?
Akari Therapeutics's international securities identification number is: US00972G1085 What is Akari Therapeutics's CUSIP number?
Akari Therapeutics's Committee on Uniform Securities Identification Procedures number is: 15119A202